NAB-Paclitaxel plus Cisplatin

Phase 2Small molecule

PPeng Liu

NAB-Paclitaxel plus Cisplatin is one of 12 small molecule programs targeting Thymoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThymomaNot yet recruiting

ThymomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Thymoma

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Approved

—2

Beleodaq

AAcrotech Biopharma Inc.

Signifor

Betadine

BBecton, Dickinson and Company

Trodelvy

1 6

Medrol

Pfizer

Phase 2

1 7

Bavencio

EMD Serono

Phase 2

1 8

Erbitux

IImclone

Phase 2

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 10

Sacituzumab Govitecan-Hziy

Gilead

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thymoma1 trial

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Not yet recruiting·PPeng Liu·Phase 2·NCT05816694·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NAB-Paclitaxel plus Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NAB-Paclitaxel plus Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NAB-Paclitaxel plus Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peng Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeng Liu

NAB-Paclitaxel plus Cisplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thymoma1 trial

References

Drug Info

Quick Facts

Related News